Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2016', provides in depth analysis on Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted pipeline therapeutics. 

The report provides comprehensive information on the Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146)
- The report reviews Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) Overview 9
Therapeutics Development 10
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Products under Development by Stage of Development 10
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Products under Development by Therapy Area 11
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Products under Development by Indication 12
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Products under Development by Companies 15
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Products under Development by Universities/Institutes 17
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Companies Involved in Therapeutics Development 23
Actinogen Limited 23
Ahn-Gook Pharmaceutical Co., Ltd. 24
Astellas Pharma Inc. 25
AstraZeneca Plc 26
Connexios Life Sciences Pvt. Ltd. 27
F. Hoffmann-La Roche Ltd. 28
Hyundai Pharmaceutical Co., Ltd. 29
Merck & Co., Inc. 30
Pfizer Inc. 31
Poxel SA 32
Sanofi 33
Shanghai Pharmaceutical Co., Ltd. 34
SK Chemicals Co., Ltd. 35
Sumitomo Dainippon Pharma Co., Ltd. 36
Toray Industries, Inc. 37
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Drug Profiles 38
ASP-3662 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
AZD-4017 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
BI-135558 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
CNX-1049 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Drug to Inhibit 11Beta-HSD1 for Hypertension - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
DSP-0011 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
HIS-388 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
HOB-046 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
HSD-621 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
KR-66344 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NCE-402 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
RG-4929 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
RO-5093151 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
SAR-184841 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase 1 for Type 2 Diabetes - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
UAI-101 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
UE-2343 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Dormant Projects 60
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Discontinued Products 62
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Featured News & Press Releases 63
Sep 29, 2016: FDA Feedback On Xanamem Alzheimers Trial 63
Jul 27, 2016: Actinogen Medical Announces Landmark Research on Excess Cortisol and Alzheimer's Disease 63
Jul 20, 2016: US Patent Granted - Further Extends Xanamem Protection 64
Mar 22, 2016: XanADu: A New Pivotal Global Clinical Trial to Treat Mild Alzheimer's Disease 64
Sep 29, 2015: Positive Trial Results for Alzheimers Drug Xanamem 65
Aug 11, 2015: Clinical Trial Successfully Completed With Xanamem-AN Alzheimers Drug 66
Jun 11, 2015: Excellent Research Progress With Xanamem - A Promising Alzheimers Drug 67
Apr 13, 2015: EU Patent Granted - Further Extends Xanamem Protection 68
Jun 05, 2013: Enzyme Could Be The Key To Aiding Wound Healing In Diabetic And Elderly People 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Assessment by Monotherapy/Combination Products, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Actinogen Limited, H2 2016 23
Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2016 24
Pipeline by Astellas Pharma Inc., H2 2016 25
Pipeline by AstraZeneca Plc, H2 2016 26
Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 27
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 28
Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 29
Pipeline by Merck & Co., Inc., H2 2016 30
Pipeline by Pfizer Inc., H2 2016 31
Pipeline by Poxel SA, H2 2016 32
Pipeline by Sanofi, H2 2016 33
Pipeline by Shanghai Pharmaceutical Co., Ltd., H2 2016 34
Pipeline by SK Chemicals Co., Ltd., H2 2016 35
Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 36
Pipeline by Toray Industries, Inc., H2 2016 37
Dormant Projects, H2 2016 60
Dormant Projects (Contd..1), H2 2016 61
Discontinued Products, H2 2016 62